Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 4Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm Metastasis 2Triple Negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 126Carboplatin 108Pemetrexed 76Paclitaxel 76Cisplatin 73Nivolumab 56Docetaxel 53Erlotinib Hydrochloride 50Gemcitabine 49Radiotherapy 48Bevacizumab 32osimertinib 31Cetuximab 29atezolizumab 25Cyclophosphamide 25durvalumab 24130-nm albumin-bound paclitaxel 22Oxaliplatin 19Fluorouracil 18Taxes 17Radiosurgery 17fludarabine 16Magnetic Resonance Spectroscopy 16Gefitinib 16Ipilimumab 15Vinorelbine 14Leucovorin 14Albumin-Bound Paclitaxel 14Vorinostat 13Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Non-Small-Cell Lung × CP protocol × Clear all
NCT03307785 2025-11-25

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Tesaro, Inc.

Phase 1 Completed
60 enrolled 91 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡